iPS Cells & Regenerative Medicine– category –
-
FDA Flags Unapproved Exosome Therapies, Citing Safety Concerns and International Regulatory Gaps
PLANEW Clinic South Korea Overview Exosome therapy is attracting significant attention for its regenerative potential, particularly in skin treatments, yet currently lacks U.S. FDA approval. The FDA has issued public safety warnings agai... -
CHOC Shapes Future of Pediatric Gene Therapy: Driving Early Intervention with CRISPR Editing and Strict Quality Control
Children's Hospital of Orange County (CHOC) Pediatrica USA Overview Rady Children's Health Orange County is focusing on in vivo gene replacement, ex vivo gene therapy (e.g., CAR T-cell therapy), and CRISPR-based genome editing to shape t... -
CRISPR Gene Editing Technology Drives Clinical Adoption: FDA’s First Approval, Casgevy, for Sickle Cell Disease and Beta Thalassemia Accelerates Clinical Translation
Britannica Global Overview CRISPR, a powerful gene-editing tool with high sequence specificity, precisely removes or inserts DNA at specific genomic locations, offering superior efficiency, reliability, and cost-effectiveness over tradit... -
ARPA-H Launches AEGIS Project: Affordable Gene-Editing Therapies for Pediatric Immune Diseases via CRISPR and LNP Delivery
Princeton University USA Overview The ARPA-H THRIVE-funded AEGIS project is pioneering the development of affordable gene-editing therapies for children suffering from rare inborn errors of immunity (IEIs). By leveraging advanced CRISPR ... -
Hopstem’s iPSC-Derived Neural Progenitor Cell hNPC01 Receives FDA IND Clearance and Fast Track Designation for Stroke and Traumatic Brain Injury
AllSci USA Overview Hopstem Biotechnology announced that its allogeneic iPSC-derived forebrain neural progenitor cell therapy, hNPC01, received both IND clearance and Fast Track designation from the U.S. FDA for treating chronic motor de... -
AI Unlocks CAR T Durability: Single-Cell Models Predict Lasting Remission, Identify Novel Biomarker in B-ALL
bioRxiv USA Overview While CD19-targeted CAR T-cell therapy offers significant hope for B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, approximately half experience relapse within a year. A new study demonstrates that single-cell ... -
FDA Flexibilizes Cell and Gene Therapy CMC Regulations, Eliminating ‘Rule of Three’ to Accelerate Development
BioProcess International USA Overview The U.S. FDA has announced a flexible Chemistry, Manufacturing, and Controls (CMC) guidance for Cell and Gene Therapy (CGT) products, effectively ending the traditional 'Rule of Three' validation req... -
4D Printing and Smart Hydrogels Revolutionize Regenerative Wound Therapy: Vascularized Scaffolds Enable Precision Drug Delivery
Polymers (PMC) Global Overview New paradigms are emerging in precision drug delivery and regenerative wound therapy, spanning from smart hydrogel design to 4D-printed scaffolds. Advances in 3D bioprinting now enable the fabrication of va... -
Ultra-Homotypic Targeting: Lanthanide-Modified EVs Boost Cancer Detection Sensitivity by Over 25-Fold
University of Tokyo Japan Overview Researchers at the University of Tokyo, led by Professor Keisuke Goda, have unveiled a groundbreaking 'ultra-homotypic targeting' technology. By engineering extracellular vesicles (EVs) with lanthanide ... -
Children’s Hospital of Philadelphia Develops CAR T-Cell Therapy for Pediatric Solid Tumors: First Human Trial Targets PHOX2B-Derived Peptides
Children's Hospital of Philadelphia (CHOP) USA Overview Researchers at Children's Hospital of Philadelphia (CHOP) are leading the development of CAR T-cell therapies for pediatric solid tumors like neuroblastoma. A 'peptide-centric' (PC-...
